Podcast: Why We Need to Discuss Gene Editing and Ethics
By Jack Murtha,
Healthcare Analytics News [with CGS' Marcy Darnovsky]
| 08. 03. 2018
In 1951, Henrietta Lacks walked into Johns Hopkins Hospital complaining of vaginal bleeding. Although she died later that year, her legacy lives on. Why? Because researchers took her cells and shared them with colleagues, conducting countless studies that have fueled findings in many areas. And they did so without her permission.
Henrietta’s story is incredible on several levels: First, her cells, transformed by radium, were unique in their ability not only to survive the laboratory but to thrive. Second, she unwittingly advanced medical and scientific research. Third, she never knew of her remarkable contribution to science, making her story a case study on consent, public trust and medical ethics.
>> READ: The Complicated Ethics of Gene Editing
Now, in 2018, gene editing is no longer the stuff of science fiction. It is real, and many gene-editing therapies, such as treatments involving chimeric antigen receptor T-cells and CRISPR, could forever change medicine. They could — no, they are ushering in the age of precision medicine. Their enormous costs have also contributed to the rise of value-based care, as certain therapies earn...
Related Articles
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...
By Jessica Hamzelou, MIT Technology Review | 11.07.2025
This week, we heard that Tom Brady had his dog cloned. The former quarterback revealed that his Junie is actually a clone of Lua, a pit bull mix that died in 2023.
Brady’s announcement follows those of celebrities like Paris...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...